AnaptysBio Reports Q2 2026 Net Income of $177.3M Driven by $181.5M Tax Benefit
ANAB has more than doubled off its 52-week low of $13.658.
Summary
AnaptysBio reported Q2 2026 net income of $177.3 million, driven by a $181.5 million non-cash tax benefit from the First Tracks spin-off. Jemperli royalties grew 34% year-over-year, and the GSK/Tesaro litigation judgment is expected in Q4 2026 or Q1 2027.
Key Events · Earnings and Guidance · ANAB
-
Q2 Net Income of $177.3M
Net income from continuing operations was $177.3 million for the three months ended June 30, 2026, or $6.06 basic EPS, compared to $5.7 million in the prior-year quarter.
-
$181.5M Non-Cash Tax Benefit
The income was driven by a $181.5 million benefit for income taxes from releasing a valuation allowance on deferred tax assets, tied to the April 2026 spin-off of First Tracks Biotherapeutics.
-
Jemperli Royalties Grow 34%
Jemperli global net sales reached $644 million for the six months ended June 30, 2026, up 34% year-over-year, with collaboration revenue of $27.5 million for the quarter.
-
Cash Declines to $164.1M
Cash, cash equivalents and investments totaled $164.1 million as of June 30, 2026, down $47.5 million from December 31, 2025, due primarily to $72.9 million in operating activities.
Analysis · ANAB · Life Sciences
A dramatic swing to profitability marks AnaptysBio's Q2 2026 results, with net income from continuing operations of $177.3 million for the quarter. This was driven almost entirely by a $181.5 million tax benefit from releasing a valuation allowance on deferred tax assets—a non-cash accounting event tied to the April 2026 spin-off of First Tracks Biotherapeutics, not operational performance. The company's core royalty business grew modestly: Jemperli global net sales rose 34% year-over-year to $644 million for the six months, and collaboration revenue increased to $27.5 million for the quarter. Cash declined to $164.1 million from $211.6 million at year-end, reflecting $72.9 million in operating cash burn. The litigation with GSK and Tesaro remains the key swing factor, with a post-trial hearing set for October 20, 2026 and a judgment expected in Q4 2026 or Q1 2027.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.